Molecular Templates, Inc.

Clinical Trials

Active, not recruiting

Diffuse Large B-Cell Non-Hodgkin's Lymphoma Clinical Trial

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.

View Clinical Trial

Active, not recruiting

Diffuse Large B-Cell Non-Hodgkin's Lymphoma Clinical Trial

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in subjects with relapsed or refractory B-Cell NHL.

View Clinical Trial

Active, not recruiting

Diffuse Large B-Cell Non-Hodgkin's Lymphoma Clinical Trial

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with gemcitabine and oxaliplatin (GEMOX) in subjects with relapsed or refractory B-Cell NHL.

View Clinical Trial

Recruiting

HER2-positive Solid Tumors Clinical Trial

This will be a Phase 1, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) in subjects with HER2-positive solid tumors.

View Clinical Trial

Recruiting

Relapsed or Refractory Multiple Myeloma (RRMM) Clinical Trial

The purpose of this study is to evaluate the safety and tolerability of TAK-169, establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to provide a preliminary evaluation of the clinical activity of TAK-169 monotherapy in participants with RRMM.

View Clinical Trial

Enrollment

For more information on enrollment in our current clinical trials, please visit clinicaltrials.gov for location information.